Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical TIL ACT for BCG Exposed High Grade NMIBC
NCT05768347Phase 1Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC101 TIL + pembrolizumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Moffitt Cancer Center. Primary endpoint: Safety of Adoptive Cell Therapy with TILs at 6 months. Started Aug 2023; status: active, not recruiting.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05768347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768347.